Brief: Cel-Sci Corp - Phase 3 Trial Showed Multikine Immunotherapy Extended Lives Of Patients With Locally Advanced Primary Scchn - Oral Cavity/Soft Palate
22/11/2022 14:09
Nov 22 (Reuters) - CEL-SCI Corp CVM.A :
* CEL-SCI CORP - PHASE 3 TRIAL SHOWED MULTIKINE
IMMUNOTHERAPY
EXTENDED LIVES OF PATIENTS WITH LOCALLY ADVANCED PRIMARY SCCHN -
ORAL CAVITY/SOFT PALATE
* CEL-SCI CORP - MULTIKINE TREATED STUDY POPULATION SHOWED A
MEDIAN OVERALL SURVIVAL IMPROVEMENT OF 46.5 MONTHS
* CEL-SCI CORP - 62.7% OF MULTIKINE PATIENTS WERE ALIVE
AFTER FIVE
YEARS VERSUS. 48.6% IN CONTROL
* CEL-SCI CORP - TUMOR SHRINKAGE/DISAPPEARANCE CUT DEATH
RATE BY A
FACTOR OF THREE
Source text for Eikon: ID:nBw6DsmvZa
Further company coverage: CVM.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CEL-SCI
See all newsBrief: CEL-SCI Announces Closing Of Offering
Brief: Cel-Sci Corp Files For Offering Of 6 Million Shares Of Common Stock- SEC Filing
Brief: Cel-Sci Corporation Announces Pricing Of Public Offering
Brief: CEL-SCI Enters Strategic Agreement With Amarox For The Registration, Commercialization, And Distribution Of Multikine In Saudi Arabia
Drug developer CEL-SCI dives on deep-discounted equity raise